JOP20230077A1 - محفزات glp 1/ gip مزدوجة - Google Patents

محفزات glp 1/ gip مزدوجة

Info

Publication number
JOP20230077A1
JOP20230077A1 JOJO/P/2023/0077A JOP20230077A JOP20230077A1 JO P20230077 A1 JOP20230077 A1 JO P20230077A1 JO P20230077 A JOP20230077 A JO P20230077A JO P20230077 A1 JOP20230077 A1 JO P20230077A1
Authority
JO
Jordan
Prior art keywords
gip
stimulators
dual glp
obesity
diabetes
Prior art date
Application number
JOJO/P/2023/0077A
Other languages
English (en)
Inventor
Vinod Sampatrao Burade
Abhishek Tiwari
Rajamannar Thennati
Dhiren Rameshchandra Joshi
Chandulal Thakarshibhai Jivani
Krunal Harishbhai Soni
Manish Harendraprasad Gandhi
Muthukumaran Natarajan
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of JOP20230077A1 publication Critical patent/JOP20230077A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Theoretical Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Software Systems (AREA)
  • Sewing Machines And Sewing (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Data Mining & Analysis (AREA)

Abstract

يتعلق الاختراع الحالي ببولي ببتيد مساعد مزدوج وممتد المفعول مكون من ببتيد شبيه بالجلوكاجون-1 وبولي ببتيد مفرز للإنسولين اعتمادًا على الجلوكوز البشري (GIP) والذي يفيد في علاج النوع 2 من البول السكري (T2D)، والسكري الناتج عن السِمنة، والسِمنة وفرط الدهون في الدم.
JOJO/P/2023/0077A 2020-10-17 2023-04-16 محفزات glp 1/ gip مزدوجة JOP20230077A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202021045240 2020-10-17
IN202121002837 2021-01-20
PCT/IB2021/059420 WO2022079639A1 (en) 2020-10-17 2021-10-13 Glp-1/gip dual agonists

Publications (1)

Publication Number Publication Date
JOP20230077A1 true JOP20230077A1 (ar) 2023-04-16

Family

ID=78302859

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0077A JOP20230077A1 (ar) 2020-10-17 2023-04-16 محفزات glp 1/ gip مزدوجة

Country Status (16)

Country Link
US (2) US20240020543A1 (ar)
EP (1) EP4204440A1 (ar)
JP (2) JP7830441B2 (ar)
KR (1) KR20230088337A (ar)
CN (1) CN116171164A (ar)
AU (1) AU2021361263A1 (ar)
BR (1) BR112023003668A2 (ar)
CA (1) CA3195155A1 (ar)
CL (1) CL2023000960A1 (ar)
CO (1) CO2023001960A2 (ar)
IL (1) IL301109A (ar)
JO (1) JOP20230077A1 (ar)
MX (1) MX2023002906A (ar)
PE (1) PE20231309A1 (ar)
TW (1) TW202229323A (ar)
WO (1) WO2022079639A1 (ar)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118754965A (zh) 2020-05-29 2024-10-11 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用
CN116171164A (zh) 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
KR20240007251A (ko) 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN117402219B (zh) 2022-07-13 2024-07-30 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
JP2025523981A (ja) * 2022-07-20 2025-07-25 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための医薬製剤及び方法
CN117756913B (zh) * 2022-11-07 2025-05-09 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
CN115651075B (zh) * 2022-12-12 2023-04-11 杭州信海医药科技有限公司 一种Tirzepatide的合成方法
AR131430A1 (es) * 2022-12-21 2025-03-19 Boehringer Ingelheim Int Agonistas triples de los receptores de glp1 / gip / npy2
IL321413A (en) * 2022-12-29 2025-08-01 Lilly Co Eli Processes and intermediates for the preparation of tirazeptide
KR20250140132A (ko) * 2023-01-18 2025-09-24 상하이 민웨이 바이오테크놀로지 씨오 엘티디 삼중 활성을 갖는 융합 단백질 및 그 용도
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
EP4716545A1 (en) * 2023-05-21 2026-04-01 Carmot Therapeutics Inc. Treatment of adults with overweight or obesity with or without weight-related comorbidities
EP4724472A2 (en) 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
AU2024408289A1 (en) 2023-12-22 2026-08-06 Tangram Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
AU2025216394A1 (en) 2024-01-31 2026-07-16 Sun Pharmaceutical Industries Ltd. High level production of glp1 analogues
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007224019A1 (en) 2006-03-03 2007-09-13 California Institute Of Technology Site-specific incorporation of amino acids into molecules
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트
CA2872314C (en) * 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
ES2602486T3 (es) * 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
CA2929459C (en) * 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
AR103242A1 (es) 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
EP4480537A3 (en) 2017-01-17 2025-03-12 Amgen Inc. Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
SMT202200352T1 (it) 2018-04-05 2022-09-14 Sun Pharmaceutical Ind Ltd Analoghi del glp-1 innovativi
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
AU2019309798A1 (en) * 2018-07-23 2021-02-11 Eli Lilly And Company Method of using a GIP/GLP1 co-agonist for diabetes
ES3068975T3 (en) 2018-07-23 2026-06-03 Lilly Co Eli Gip/glp1 co-agonist compounds
AU2020256648B2 (en) 2019-04-11 2026-01-15 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Multi-receptor agonist and medical use thereof
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型glp-1/gip雙重促效劑
CN116171164A (zh) 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂

Also Published As

Publication number Publication date
US20240020543A1 (en) 2024-01-18
WO2022079639A1 (en) 2022-04-21
IL301109A (en) 2023-05-01
CO2023001960A2 (es) 2023-05-08
KR20230088337A (ko) 2023-06-19
PE20231309A1 (es) 2023-08-24
AU2021361263A1 (en) 2023-02-16
JP7830441B2 (ja) 2026-03-16
TW202229323A (zh) 2022-08-01
US20240400613A1 (en) 2024-12-05
CN116171164A (zh) 2023-05-26
CL2023000960A1 (es) 2023-11-10
JP2023545662A (ja) 2023-10-31
US12622948B2 (en) 2026-05-12
JP2026086912A (ja) 2026-05-26
MX2023002906A (es) 2023-04-05
CA3195155A1 (en) 2022-04-21
BR112023003668A2 (pt) 2023-04-25
EP4204440A1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
MX2023002906A (es) Agonistas duales glp-1/gip.
JOP20220344A1 (ar) عوامل مساعدة glp-1/gip مزدوجة ممتدة المفعول
ZA202106369B (en) Gip/glp1 co-agonist compounds
MX2021005835A (es) Compuestos co-agonistas de gip y glp-1.
MY205796A (en) Gipr-agonist compounds
MX2021015328A (es) Agonistas del receptor del peptido-1 similar al glucagon.
WO2010054326A3 (en) C-terminal fragments of glucagon-like peptide-1 (glp-1)
MX2022009149A (es) Compuestos coagonistas de gip/glp1.
MX2023014740A (es) Tratamiento de la obesidad y trastornos relacionados con la obesidad.
AU2019378845A8 (en) Combination treatment of NAFLD and NASH
MX2026000195A (es) Triagonista de los receptores glp-1, gip y gcg y su uso
ECSP23019850A (es) Agonistas duales glp-1/gip
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
TH2101000319A (th) สารประกอบอะโกนิสท์ร่วม gip/glp1